AUTHORS
Gao Yan, PhD, Xuan-Ye Zhang2, Xue-Ping Li3, Xiaolei Wei4, Qichun Cai, PhD5, Jicheng Hong6, Li-Qin Ping7, Huiqiang Huang, MD, PhD8
AFFILIATIONS
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Sun Yat-sen University Cancer Center, Guangzhou, China
3 Sun Yat-sen University Cancer Center, Guangzhou, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, China
5 Cancer Center, Clifford Hospital, Guangzhou, China
6 Sun Yat-sen University Cancer Center, Guangzhou, China
7 The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China
8 Sun Yat-sen University Cancer Center, Guangzhou, China
ABSTRACT
Background
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with higher prevalence in Asia. The P-GemOx regimen (pegaspargase, gemcitabine, oxaliplatin) is a standard first-line therapy with favorable toxicity. Our previous SCENT trial demonstrated that sintilimab (anti-PD-1) plus chidamide (HDAC inhibitor) was safe and effective in relapsed/refractory (r/r) ENKTL. Given the potential synergy, we hypothesized that upfront sequential therapy with SC followed by P-GemOx could improve outcomes in treatment-naïve (TN) patients. We previously reported early-stage data; here we update those and present first outcomes for advanced-stage disease.
Methods
This investigator-initiated, multicenter, phase II trial (NCT04994210) enrolled patients aged 18–80 with histologically confirmed TN ENKTL. Early-stage patients received two cycles of SC (sintilimab + chidamide) at standard doses (SC×2). Those achieving complete (CR) or partial response (PR) after SC×2 then received two cycles of P-GemOx (P-GemOx×2); those with stable (SD) or progressive disease (PD) received four cycles (P-GemOx×4). All early-stage patients underwent involved-field radiotherapy (IFRT) after P-GemOx. For advanced-stage patients, those achieving CR/PR after SC×3 proceeded to P-GemOx×3, whereas those with SD/PD received P-GemOx×6. Patients aged <60 years with CR after P-GemOx were eligible for autologous stem cell transplantation (ASCT); others received one year of SC maintenance. The primary endpoint was CR rate (CRR) after P-GemOx. Secondary endpoints included overall response rate (ORR) after P-GemOx, CRR after SC, progression-free survival (PFS), overall survival (OS), and safety. Simon’s two-stage optimal design was used. For early stage, assuming an expected CRR of 80% with a minimum acceptable 60%, the design required 7 responses in first 11 and total 23 of 32; for advanced, assuming 70% vs 40%, required 3 of 7 and 8 of 13. With 10% dropout, total sample sizes were 47 and 22 for early and advanced, respectively. All responses were assessed per Lugano criteria using PET/CT.
Results
From August 2022 to April 2026, 65 eligible patients (47 early, 21 advanced) were enrolled from three centers. All had PET/CT for response assessment. In the early-stage cohort, after SC×2, ORR was 80.8% (38/47) with CRR 63.8% (30/47); median cycles of SC and P-GemOx were 2 each. After P-GemOx, among 45 evaluable patients, CRR was 97.7% (44/45). In the advanced cohort, after SC×3, ORR was 57.1% (12/21) and CRR 14.3% (3/21); after P-GemOx, among 20 evaluable, ORR was 95.0% (19/20) and CRR 75.0% (15/20). Median cycles of SC and P-GemOx were 3 and 6, respectively. Median follow-up for overall, early, and advanced were 28.3, 32.1, and 15.3 months. Overall 2-year PFS was 84.0% (95% CI, 72.2–91.1) and OS 75.6% (95% CI, 63.3–84.3). For early stage, 3-year PFS was 84.9% (95% CI, 70.8–92.5) and OS 83.0% (95% CI, 68.8–91.1). For advanced stage, 1-year PFS was 83.5% (95% CI, 56.8–94.4) and OS 64.6% (95% CI, 39.7–81.3). Common all-grade myelotoxicities: neutropenia 93.1%, lymphopenia 87.9%, anemia 67.2%, thrombocytopenia 56.9%. Non-hematologic: decreased appetite 39.2%, nausea 51.7%, elevated lipase 32.8%. Most toxicities were attributed to P-GemOx.
Conclusions
The SCENT 2 trial met its primary endpoint, demonstrating high CR rates with this chemo-reduced sequential strategy. The regimen showed promising efficacy with manageable toxicity, particularly in early-stage disease. Further research is warranted to validate these findings and explore optimal integration of immunotherapy and chemotherapy.
DISCLOSURES
Huiqiang Huang, MD, PhD: No relevant conflicts of interest to declare.